William Blair & Company
CHRS icon

William Blair & Company’s Coherus Oncology CHRS Stock Holding History

William Blair & Company’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,000
Closed -$27K – 1936
2025
Q4 		$27K Buy
+19,000
New +$27.7K ﹤0.01% 1708

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

William Blair & Company's CHRS Position: Q1 2026 in Review

William Blair & Company sold out of Coherus Oncology (CHRS) in Q1 2026, closing a stake of 19,000 shares — an estimated $27K sold.

William Blair & Company first reported a position in CHRS in Q4 2025 and held it in 1 quarter. The position peaked at $27K in Q4 2025. 158 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • William Blair & Company reported no remaining Coherus Oncology position as of Q1 2026 after selling out during the quarter.
  • William Blair & Company sold 19,000 Coherus Oncology shares in Q1 2026, an estimated $27K.
  • William Blair & Company first reported a position in Coherus Oncology in Q4 2025 and held it in 1 quarter.
  • William Blair & Company's Coherus Oncology position peaked at $27K in Q4 2025.
  • 158 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.